Pepticom's New Spinout Company, PeptiCov, to Focus on COVID-19
Pepticom's New Spinout Company, PeptiCov, to Focus on COVID-19 JERUSALEM, March 9, 2021 /PRNewswire/ -- Pepticom, a leader in artificial intelligence peptide drug design and discovery, announced today that it has raised $2.6 million to establish a company to focus on treatments for the SARS-Cov-2 virus, responsible for the COVID-19 outbreak. The company, PeptiCov, will implement Pepticom's AI technology to design, discover and develop novel peptide molecules for effective treatment of the SARS-Cov-2 virus. The funding round was led by the Chartered Group. "Unfortunately, COVID-19 and the vari...
Source: finanznachrichten.de